# GutHeart: Targeting Gut Microbiota to Treat Heart Failure

> **NCT02637167** · PHASE2 · UNKNOWN · sponsor: **Oslo University Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Systolic Heart Failure

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Saccharomyces boulardii

## Key facts

- **NCT ID:** NCT02637167
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03-11
- **Primary completion:** 2019-06-20
- **Final completion:** 2019-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02637167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02637167, "GutHeart: Targeting Gut Microbiota to Treat Heart Failure". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02637167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*